Progress reported on one-dose J&J vaccine; COVID-19 reinfections seen as rare

The following is a roundup of some of the latest scientific studies on the novel coronavirus and efforts to find treatments and vaccines for COVID-19, the illness caused by the virus. Johnson & Johnson vaccine advancing through clinical trials An experimental COVID-19 vaccine from Johnson & Johnson produced protective antibodies against the novel coronavirus in 90% of 805 volunteers by 29 days, and that increased to 100% by day 57, according to data from an ongoing mid-stage study. Side effects such as fever, muscle aches and injection site pain resolved quickly, researchers reported on Wednesday in the New England Journal of Medicine. To be approved by regulators, the J&J vaccine must show efficacy as reflected by a lower risk of infections and severe disease in study participants who receive it compared to those who do not. Efficacy data from a large late-stage trial on the vaccine is due by February